文献速递垂体与肾上腺疾病

周期性库欣综合征的周期特征与临床并发症:国际回顾性队列研究

Cycle characterisation and clinical complications in patients with cyclic Cushing's syndrome: insights from an international retrospective cohort study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-10-23

该国际回顾性研究纳入21国43个内分泌中心的110例确诊周期性库欣综合征患者,刻画其周期模式、峰值频率与并发症。研究显示异位来源者峰值最频繁严重,诊断延迟、错误手术及自发肾上腺功能不全发生率高,提示需在BIPSS前生化确认高皮质醇血症并做好动态监测。

要点

  • 异位周期性库欣综合征的皮质醇峰值最频繁且最严重
  • 周期多不规则,峰值时症状加重、低谷时改善
  • BIPSS前须生化确认高皮质醇血症以避免定位错误

核心结论

  • 周期性库欣综合征即使在内分泌专科中心,诊断与治疗仍具挑战,自发肾上腺功能不全、不当手术与不良结局发生率高。
  • 异位周期性库欣综合征的峰值最频繁且最严重,研究结果可能有助于指导影像定位或活动性隐匿性ACTH依赖性周期性库欣综合征患者BIPSS的时机。

研究设计与样本

  • 多中心回顾性观察研究,覆盖21个国家43个内分泌中心。
  • 纳入确诊库欣综合征且出现≥2次高皮质醇峰值和≥1次自发正常或低皮质醇低谷的患者,共110例(初筛116例)。

主要发现

  • 来源:垂体70例(64%)、异位25例(23%)、肾上腺3例(3%)、隐匿12例(11%)。
  • 峰值时症状加重87/108(81%),低谷时改善79/107(74%),自发肾上腺功能不全31/110(28%)。

关键数值与推荐

  • 78次BIPSS中14次(18%)于低谷期进行。
  • 影像学漏诊肿瘤35/110(32%),9/110(8%)因错误分类在错误解剖部位接受不必要手术。
  • 诊断延迟45/110(41%),治疗延迟47/110(43%)。

临床怎么用

  • BIPSS前需生化确认高皮质醇血症,以实现正确的肿瘤定位。
  • 疑似或确诊周期性库欣综合征患者应配备唾液皮质醇采集工具以捕捉动态变化,并处方糖皮质激素备用。

局限性

  • 为回顾性观察研究,可能存在选择与记录偏倚。
  • 数据来自专科中心,外推至一般人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cyclic Cushing's syndrome (cCS) features fluctuating cortisol secretion, often causing diagnostic errors or delays, and possibly poorer outcomes. We aimed to identify unpublished cCS cases to characterise clinical challenges and guide strategies for improving outcomes by characterising cycle patterns, peak frequency, and evaluating complications. METHODS: This was a retrospective observational study at 43 endocrine centres in 21 countries, including patients with confirmed Cushing's syndrome showing two or more hypercortisolaemic peaks and one or more spontaneous eucortisolaemic or hypocortisolaemic trough. Data included both clinical (eg, comorbidities and physical signs of cortisol excess) and biochemical (eg, screening and confirmatory tests) parameters, imaging, treatment, complications, and outcomes. FINDINGS: Between Dec 1, 2023 and Feb 2, 2025, 116 potentially eligible patients were identified and 110 were included. Most patients were female (84 [76%] of 110 patients), with a median age at diagnosis of 44·0 years (IQR 31·8-58·3). cCS origin was pituitary in 70 (64%), ectopic in 25 (23%), adrenal in three (3%), and occult in 12 (11%). Cyclicity was primarily determined by 24 h urinary free cortisol, with median peaks of 7·40 × ULN (range 0·44-299) and troughs of 0·31 × ULN (0·02-0·98). The median peak count was 3·0 (IQR 2·0-4·0), mostly (55 [86%] of 64 patients) occurring at irregular intervals, and was most frequent and pronounced in ectopic cCS. Symptoms worsened in 87 (81%) of 108 patients during peaks and improved in 79 (74%) of 107 patients during troughs; 31 (28%) of 110 patients had spontaneous adrenal insufficiency. Bilateral inferior petrosal sinus sampling (BIPSS) was performed during troughs in 14 patients (18% of the 78 procedures done). Imaging missed tumours in 35 (32%) of the 110 patients, and nine (8%) underwent unwarranted surgeries at the wrong anatomical site due to misclassification. After 5·8 years (IQR 2·6-10·5) median follow-up, 55 (50%) of 110 patients had complete biochemical surgical remission, seven (6%) had spontaneous remission, 22 (20%) were medically controlled, six (5%) had partial remission, 11 (10%) remained uncontrolled, nine (8%) were lost to follow-up. During the entire observation period, 3% (3/110) died. Delayed diagnosis (45 [41%] of 110 patients) and therapy (47 [43%]) were also observed. INTERPRETATION: Even in specialised centres, cCS diagnosis and management remain challenging with high rates of spontaneous adrenal insufficiency, inappropriate surgeries, and poor outcomes. Ectopic cCS showed the most frequent and severe peaks. These findings might help to guide imaging localisations or the timing of BIPSS in patients with active occult ACTH-dependent cCS. Hypercortisolism needs to be biochemically confirmed before BIPSS to enable correct tumour localisation. Patients with suspected or proven cCS should be equipped with salivary cortisol collection kits to capture dynamic changes as well as being prescribed glucocorticoids to be used as a precaution. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Nowak E, Zhang Q, Zhang S, et al. Cycle characterisation and clinical complications in patients with cyclic Cushing's syndrome: insights from an international retrospective cohort study. Lancet Diabetes Endocrinol. 2025. PMID: 41235993. doi:10.1016/S2213-8587(25)00249-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。